DOI (2,5-Dimethoxy-4-iodoamphetamine) is a long-acting psychedelic compound belonging to the substituted amphetamine family. It is primarily known for its potent visual effects, extended duration, and stimulant-like properties. Originally synthesized in the 1970s by Dr. Alexander Shulgin, DOI has gained attention in both psychonaut and research circles for its ability to significantly alter perception, cognition, and emotional states through powerful serotonin receptor interaction — particularly at 5-HT2A sites.

• Chemical Classification: DOI is a substituted phenethylamine with structural similarity to DOM, DOB, and the 2C series. It acts as a selective partial agonist at serotonin receptors, primarily 5-HT2A and 5-HT2C, which are deeply involved in perception and mood.

• Historical Background: First described in PiHKAL (Phenethylamines I Have Known And Loved) by Dr. Shulgin, DOI was noted for its intense visuals, lengthy effects, and introspective qualities. It was initially researched for psychopharmacological applications and receptor mapping.

• Psychoactive Profile: DOI induces significant alterations in visual perception, thought patterns, time experience, and tactile sensitivity. Many users report complex geometric visuals and synesthesia.

• Typical Use Cases: It is often used for exploratory psychedelic experiences, scientific studies of serotonin receptor function, and as a research chemical in pharmacological assays.

• Legal and Scientific Relevance: Though restricted in some countries, DOI remains a key tool in neuroscience for studying hallucinogenic mechanisms and serotonin-driven behavior models.

DOI is known for its vivid and long-lasting psychedelic effects that can span up to 30 hours. These effects encompass not only visual hallucinations but also deep psychological shifts, emotional changes, and physical stimulation. The intensity and nature of these effects can vary depending on the dose, environment, and individual neurochemistry.

• Visual Effects: DOI produces bright, high-resolution geometric patterns, color enhancement, and movement distortions. These visuals often include fractals, kaleidoscopic overlays, and light tracers.

• Cognitive Effects: Users report heightened analytical thinking, abstract thought loops, and enhanced introspective awareness. This may lead to deep self-reflection or philosophical insights.

• Emotional Effects: Emotional states are often intensified, leading to profound joy, curiosity, or in some cases, anxiety. Emotional lability should be anticipated and managed through proper setting.

• Perception of Time: Many users experience drastic time distortion. Minutes may feel like hours, and vice versa, contributing to DOI’s perceived duration.

• Tactile and Auditory Enhancements: Sounds can become richer or distorted, and physical sensations more pronounced. Some report synesthesia, where senses blend together.

• Stimulatory Properties: Unlike tryptamines like psilocybin or DMT, DOI tends to increase energy, alertness, and restlessness, making it difficult to sleep even long after the peak.

• Afterglow or Residual Effects: Users often report lingering sensations or mental clarity for several hours or even a day post-trip, especially with higher doses.

One of DOI’s defining characteristics is its extreme duration. A single dose can influence perception and cognition for well over 24 hours, which makes preparation and scheduling essential before use. Its extended action is due to its strong binding affinity and resistance to metabolic breakdown in the body.

• Onset: Typically begins 1 to 2 hours after ingestion. The slow build-up may initially seem mild but intensifies rapidly once active.

• Peak: Most users report the peak effects occurring between 3 and 8 hours post-consumption, marked by strong visuals and cognitive shifts.

• Total Duration: Depending on the dose, the full experience can last between 16 and 30 hours, with larger doses stretching toward the upper limit.

• Comedown Phase: After the peak, effects taper off gradually but can remain subtly active for several hours. Restlessness or mental stimulation may continue long into the following day.

• Sleep Interference: Due to its long half-life and stimulating effects, it is common for users to be unable to sleep for at least 12 hours after dosing.

• Integration Time: The sheer length and intensity often require a full recovery day post-experience. Users are advised to avoid work or social obligations the day after.

The legal status of DOI varies significantly by region. While it is a controlled substance in some countries, it remains unscheduled or falls under grey-area analog laws in others. Anyone interested in acquiring DOI must familiarize themselves with their local legislation to avoid legal complications.

• United States: DOI is classified as a Schedule I substance under federal law, making possession, manufacture, or distribution illegal without a DEA license.

• European Union: Regulations vary by country. DOI is explicitly illegal in nations like the UK and Germany but remains unscheduled in others.

• Canada and Australia: Both countries consider DOI a controlled substance under their respective analog drug laws, despite not always being listed by name.

• Analog Laws: In places where DOI is not explicitly banned, it may still be considered illegal under “analog” legislation if deemed chemically or functionally similar to a prohibited drug.

• Research Use: In select jurisdictions, DOI may be legally purchased and handled for scientific or analytical use by institutions or credentialed researchers.

• Shipping Limitations: At Psycho Plug, we only ship DOI to regions where it is legally permissible or not explicitly controlled, reducing the risk of seizures or legal repercussions.

Due to its high potency and long-lasting nature, precise dosing of DOI is critical. A small variation in dosage can significantly alter the intensity and duration of the experience. Measurement should always be done with an accurate milligram or microgram scale.

• Threshold Dose: Around 0.25 mg. At this level, effects may be limited to light stimulation and very mild perceptual shifts.

• Common Active Dose: Between 1.0 mg and 2.5 mg. This is the most reported dose range, producing strong visuals and significant cognitive effects.

• High Dose: 3.0 mg or more. Such doses lead to very intense psychedelic effects, extended duration, and greater physical stimulation.

• Titration Strategy: First-time users should start at or below 1.0 mg to assess sensitivity, gradually increasing in future sessions as needed.

• Microdosing: While possible, DOI is not ideal for microdosing due to its long duration and stimulatory nature. Microdoses usually fall in the 0.05–0.1 mg range.

• Importance of Accuracy: Using a scale with 0.001g (1mg) precision is essential. Liquid dilution may also be used for precise volumetric dosing.

• Risks of Overdosing: Overconsumption can lead to panic, cardiovascular strain, insomnia, and extreme cognitive disorientation. Never eyeball doses.

Proper storage of DOI is critical for maintaining its chemical stability, potency, and usability over time. Since DOI is sensitive to environmental conditions, especially light, heat, and moisture, the way it’s stored can significantly affect its shelf life and overall reliability. Ensuring proper containment and labeling is especially important for long-term preservation or scientific use.

• Store in an Airtight Container: Exposure to air and humidity can degrade DOI’s potency. Use tightly sealed containers, preferably vacuum-sealed or with moisture absorbers, to prevent oxidation.

• Keep in a Cool, Dry Place: Store at room temperature or slightly cooler, away from heat sources like electronics or direct sunlight. Heat accelerates chemical breakdown.

• Protect from Light: Light, especially UV rays, can deteriorate the molecular structure. Use amber glass vials or store in opaque containers to block exposure.

• Avoid Contaminants: Cross-contamination with other chemicals or moisture may alter DOI’s integrity. Always use clean, dry instruments when handling the product.

• Label Clearly: Include the name, concentration, batch number, and date of acquisition on each container. This ensures correct usage and traceability for research or dosage control.

• Long-Term Storage: For extended storage beyond six months, refrigeration is advised. Do not freeze the product unless it’s specifically prepared for freezing and stored in moisture-proof packaging.

• Keep Out of Reach: DOI should always be stored safely away from children, pets, or unauthorized individuals to prevent accidental exposure or misuse.

When used responsibly and in an informed setting, DOI has a relatively low physical toxicity profile. However, due to its extreme potency and long-lasting psychological effects, it requires careful handling and preparation. The potential risks lie more in the mental and emotional domains than in physical toxicity, and unsafe environments can lead to distressing experiences.

• Low Physical Toxicity: DOI does not carry high toxicity at standard dosages and is not associated with organ damage or acute toxicity in healthy individuals.

• High Psychological Intensity: The mental effects can be overwhelming, especially in unprepared users or chaotic environments. This includes anxiety, confusion, or panic attacks.

• Risk of Overstimulation: Its amphetamine-like structure can cause elevated heart rate, restlessness, and insomnia — especially at higher doses or in combination with other stimulants.

• Not Suited for All Users: Individuals with underlying mental health conditions such as schizophrenia, bipolar disorder, or severe anxiety disorders should avoid DOI.

• No Documented Fatalities at Standard Use: There are no confirmed cases of fatal DOI overdoses at responsible dosage levels, though extremely high doses can lead to serious psychological events.

• Set and Setting Crucial: A calm, safe, and familiar environment dramatically reduces the risk of a negative experience and improves outcomes.

• Harm Reduction Practices: Having a sober trip-sitter, hydration, and pre-education on effects greatly improves safety and reduces post-trip stress or confusion.

Mixing DOI with other substances is generally discouraged due to its strong pharmacological effects and long duration. Combining it with other drugs — whether legal or illicit — can lead to unpredictable interactions, increased risk of harm, and complications that may be difficult to manage during such an extended experience.

• Avoid Stimulants: Combining DOI with other stimulants like amphetamines, MDMA, or cocaine can lead to dangerous increases in heart rate, blood pressure, and anxiety.

• Risky with Depressants: Alcohol or benzodiazepines can dampen the psychedelic experience but also create toxic combinations that strain the heart and liver.

• Psychedelic Combinations: Mixing with LSD, psilocybin, or DMT can result in overwhelming sensory and cognitive overload, increasing the likelihood of confusion or paranoia.

• Prescription Drug Interactions: SSRIs, antipsychotics, and MAOIs may interfere with DOI’s serotonin-based action or pose serotonin syndrome risks — a potentially fatal condition.

• Cannabis Sensitivity: Some users find that cannabis enhances visuals or reduces nausea, but others report it increases paranoia or confusion, especially during the peak.

• Unsafe with MAOIs: Monoamine oxidase inhibitors dramatically intensify serotonergic compounds and should never be mixed with DOI due to seizure and serotonin toxicity risk.

• Unknown Synergies: Because DOI is not widely researched in combination, most drug interactions are poorly documented. The safest approach is to take DOI on its own.

While both DOI and LSD are powerful serotonergic psychedelics, they differ significantly in duration, mental profile, body effects, and visual output. Understanding these differences is crucial for choosing the right compound for specific intentions, whether that be introspective exploration, creative expansion, or psychonautical curiosity.

• Duration: DOI lasts up to 30 hours, making it more than twice as long as LSD (which typically lasts 8–12 hours). This affects planning, recovery, and sleep patterns.

• Visuals: DOI visuals are sharper, more geometric, and often more fractalized, while LSD visuals tend to be fluid, organic, and pastel-like in quality.

• Body Load: LSD is often smoother physically, whereas DOI has a more stimulating effect, which can feel jittery or physically activating for some.

• Mental Effects: LSD often facilitates emotional processing and open-ended creativity. DOI can feel more analytical, with a tendency toward abstract thinking and mental looping.

• Onset and Come-Up: LSD’s onset is faster (30–60 minutes), while DOI can take up to 2 hours to fully manifest, sometimes leading users to mistakenly redose early.

• Aftereffects: DOI’s stimulation can prevent restful sleep even long after the experience ends, while LSD’s afterglow is typically gentler and less intrusive.

• Suitability: LSD is often favored by beginners due to its softer physical profile and shorter duration. DOI is generally better suited for experienced users seeking a deeper or more experimental trip.

DOI’s historical roots are embedded in psychedelic research, particularly during the resurgence of experimental psychopharmacology in the 1970s. It gained recognition as one of the key hallucinogenic amphetamines synthesized and tested by Alexander Shulgin, contributing significantly to our understanding of serotonergic pathways and psychedelic mechanisms.

• Discovery by Alexander Shulgin: Synthesized in the mid-1970s, DOI was featured in the book PiHKAL, where Shulgin described its intense visuals, intellectual effects, and notably long duration.

• Scientific Interest: DOI has been used extensively in lab research to map serotonin receptors, especially 5-HT2A, making it a valuable compound for studying mood, cognition, and perception.

• Pharmacological Research: It became a tool for investigating how psychedelic compounds affect neuroplasticity and brain connectivity, contributing to early theories on how psychedelics promote therapeutic change.

• Psychedelic Community Usage: Though not as mainstream as LSD or psilocybin, DOI gained popularity among experienced psychonauts due to its intensity and clarity.

• Legal Regulation: Its long-lasting and powerful nature prompted regulatory attention, with the U.S. and several other countries placing it under strict control by the early 2000s.

• Modern Applications: While less common in therapeutic circles due to duration, DOI is still used in receptor mapping, psychopharmacological trials, and animal behavior models.

DOI is not considered physically addictive, and it does not cause compulsive use or chemical dependence like opioids, alcohol, or stimulants. However, due to its psychological intensity and unique effects, it may lead to habitual or reckless use in certain individuals if not approached with respect and caution. Understanding its psychological appeal and managing use frequency is key to responsible interaction with this compound.

• No Physical Dependency: DOI does not produce withdrawal symptoms, nor does it create the kind of cravings associated with physically addictive substances. Users can stop without facing physical distress.

• Rapid Tolerance Build-Up: After one dose, tolerance develops almost immediately, meaning repeated use over several days has diminished or no effect. This naturally limits repeated intake.

• Low Abuse Potential: The intensity, duration, and mental exhaustion of a DOI trip typically discourage frequent use, further reducing the risk of addiction.

• Psychological Attachment: Some individuals may feel drawn to DOI’s visual power or mental clarity, leading to overuse. This is a matter of habit, not addiction in the clinical sense.

• No Dopaminergic Reinforcement: DOI doesn’t act strongly on dopamine pathways, which are typically responsible for reward-seeking behavior in addictive drugs.

• Harm Reduction Practices: Users are encouraged to space trips by at least two weeks, keep logs of experiences, and avoid using DOI as an escape from personal problems or mental health issues.

• Integration Support: Post-trip journaling, community discussions, or working with integration coaches can help manage psychological attraction and maintain balance.

At Psycho Plug, we offer DOI in several forms to meet diverse user preferences and research needs. Each form is precisely dosed or prepared for accurate and safe use. The form you choose may depend on how comfortable you are with measuring substances or your intended method of administration.

• Powder: Highly pure crystalline DOI, ideal for volumetric dosing or scientific research. Requires a milligram- or microgram-accurate scale for safe measurement.

• Pellets/Tablets: Pre-dosed and pressed into 1.0 mg or 2.0 mg units. These are ideal for ease of use, accurate dosing, and reduced handling risk.

• Liquid Solution: DOI dissolved in ethanol or distilled water, often at concentrations like 1 mg/ml. This form allows precise microdosing or titration using droppers.

• Blotters (Rare): Occasionally, DOI may be sold on blotter paper, but this is less common due to its long duration and high potency, which require careful control.

• Lab-Grade Packaging: All forms come sealed in moisture-resistant, light-proof packaging to ensure product stability.

• Batch Testing: Each form undergoes rigorous testing for purity, identity, and consistency before sale, ensuring reliable effects and dosing accuracy.

• Educational Use Labeling: While offered for research and educational purposes, we include full handling and safety guidance with every purchase.

DOI can be microdosed, but it is rarely used for this purpose due to its extremely long half-life and stimulating effects. Unlike LSD or psilocybin, DOI remains active in the body for over 24 hours, which complicates traditional microdosing schedules. Still, some experimental users and researchers have explored its low-dose effects.

• Uncommon Choice: DOI is not among the most popular microdosing substances. Its duration makes it impractical for standard schedules like every third day.

• Typical Microdose Range: Doses between 50 mcg (0.05 mg) and 150 mcg (0.15 mg) are considered microdoses. Even these low amounts may cause noticeable effects in sensitive individuals.

• Perceived Benefits: Some users report increased focus, mental clarity, and heightened creativity, though anecdotal reports are mixed and not well-studied.

• Risks of Overstimulation: Even at microdoses, DOI may cause lingering energy, jaw tension, or sleep disturbances. It is not ideal for people prone to anxiety or insomnia.

• Accurate Dosing Required: Due to its potency, liquid volumetric dosing is often safer and more precise than trying to cut solid powder into fractions.

• Lack of Scientific Data: There are no clinical studies or established microdosing protocols for DOI, making its long-term safety profile in this context uncertain.

• Alternative Options: LSD, 1P-LSD, and psilocybin are generally considered more suitable for microdosing due to their shorter half-lives and gentler stimulation.

While DOI is physically safe at common dosages, it can cause several side effects, especially in the physical and emotional domains. These effects are usually temporary and manageable but can be distressing if unexpected or unprepared for. Being aware of the potential side effects helps users navigate the experience more confidently.

• Increased Heart Rate and Blood Pressure: Like many phenethylamines, DOI may produce cardiovascular stimulation, especially at higher doses or during intense moments.

• Insomnia and Restlessness: Due to its long half-life, users often report an inability to sleep for 12–24 hours after dosing.

• Jaw Tension or Muscle Clenching: Tension in the face, jaw, or limbs is common, especially during peak stimulation phases.

• Mild Nausea or Gastrointestinal Upset: Some users report queasiness at onset, which usually subsides during the peak.

• Anxiety or Paranoia: The intensity of visuals or thought loops can trigger discomfort or panic, particularly in high doses or challenging environments.

• Vasoconstriction: Cold extremities or a feeling of tension in the limbs may occur due to tightened blood vessels.

• Emotional Instability: Mood swings or vulnerability may arise during or after the trip. Journaling or speaking with a trusted friend can aid post-trip integration.

• Visual Fatigue: Prolonged visuals may cause eye strain or visual tracers that linger for hours post-trip, especially in dark settings.

While it is possible to take DOI alone, it is generally safer to have a trusted person present, especially for high doses or first-time experiences. DOI’s long duration and powerful effects make it unsuitable for solo use unless the user is highly experienced, well-prepared, and in a controlled environment.

• Preparation Is Key: Solo tripping requires mental readiness, physical comfort, and a secure space where interruptions are unlikely.

• Mental Resilience Needed: Without a trip-sitter, there’s no external support during difficult moments. Emotional preparedness is essential.

• Emergency Planning: Keep a phone, hydration, calming music, and grounding tools nearby. Know when to stop and how to reach help if needed.

• Experience Level Matters: Solo use should be reserved for those who have navigated psychedelics before and are familiar with DOI’s intensity and timeline.

• Set and Setting Crucial: A tidy, familiar, and quiet environment reduces risk and promotes a more positive experience.

• Inform Someone: Let a friend or contact know that you’re embarking on a journey and set a check-in time to ensure safety without constant supervision.

• Avoid High Doses: If taking DOI alone, use lower to moderate doses to maintain a manageable mental state.